Epoetin Zeta
drugOn this page
Also known as Epoetina dsetaEpoetine zetaRetacritSilapo
Summary
Epoetin Zeta (CHEMBL2108593) is an approved protein; indicated across 4 conditions including chronic kidney disease and anemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- Indications: 4 conditions
- Clinical trials: 1
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108593 |
| Name | Epoetin Zeta |
| Type | Protein |
| Max phase | 4 |
Also known as: Epoetin zeta, Epoetina dseta, Epoetine zeta, Retacrit, Silapo, EPOETIN ZETA
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| chronic kidney disease | 4 | MONDO:0005300 | EFO:0003884 |
| anemia | 4 | MONDO:0002280 | EFO:0004272 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 1.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03598582 | PHASE4 | COMPLETED | Biological Predictive Factors of Response to ESA in Low Risk MDS Patients |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: chronic kidney disease, anemia